Attending the I.N.N.O.VA.T.E meeting means being part of a significant gathering of researchers engaged in neoadjuvant immunotherapy clinical and translational research with the goal of highlighting clinical advances, innovative research approaches, as well as possibilities for collaboration and opportunities to harmonize approaches across cancers.

The aim of the meeting is to deepen the correlation of treatment approaches across cancers: immune checkpoint blockade (ICB) has revolutionized outcomes for patients with advanced cancers. Building upon this marked success, evaluation of ICB in patients with surgically resectable disease has been pursued across multiple cancer types. In addition to an improvement in operability, improving the anti-tumor immune response, as measured by pathologic response, neoadjuvant immunotherapy continues to demonstrate correlation with improved risk or recurrence across and has resulted in changes in standard of care.

Complete pathologic response to neoadjuvant treatment has previously been established a surrogate endpoint in some cancers, but data continue to emerge supporting evaluation of this understanding in the context of neoadjuvant ICB and outcomes associated with pathologic response to immunotherapy is actively being pursued across cancers.

The I.N.N.O.VA.T.E meeting will consist of invited speakers, experts from around the world, and panel discussions on a variety of topics. This will include disease specific field overviews, pathology, biomarkers, imaging and patient reported outcomes.

Join us at #I.N.N.O.VA.T.E meeting!